Ferroptosis can interact with the pathological processes of stroke through different pathways, including iron, lipid peroxidation, and amino acid metabolism processes. Studies have confirmed that inhibitors targeted ferroptosis have potential therapeutic effects in the treatment of stroke. Therefore, Ace Neuroscience offers a comprehensive service from the identification of ferroptosis targets to the pharmacological evaluation of ferroptosis inhibitors in stroke to promote the research of stroke drugs targeting ferroptosis.
Current studies have shown that targeting the lipid peroxidation process, ACSL4, system Xc-, GPX4, and other targets can effectively block ferroptosis in stroke, but the number of targets is still limited and there is still a need to find more targets to target ferroptosis in stroke. Therefore, Ace Neuroscience has established a specific platform for the identification and characterization of targets targeting the ferroptosis process in stroke.
After screening for potential targets of ferroptosis in stroke, we perform high-throughput screening of ferroptosis inhibitors against the targets to identify drugs with potential therapeutic activity in stroke. Thus, Ace Neuroscience provides a platform for high-throughput screening against ferroptosis inhibitors and provides experimental models of ferroptosis to validate the effects of candidate inhibitors.
We have demonstrated the inhibition of ferroptosis by candidate ferroptosis inhibitors. Immediately after, we offer various pharmacological activity assessment services to test the therapeutic efficacy of candidate ferroptosis inhibitors against stroke.
If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.